As of May 29
| +0.44 / +0.09%|
The 23 analysts offering 12-month price forecasts for Regeneron Pharmaceuticals have a median target of 517.00, with a high estimate of 600.00 and a low estimate of 381.00. The median estimate represents a +0.87% increase from the last price of 512.56.
The current consensus among 25 polled investment analysts is to Buy stock in Regeneron Pharmaceuticals. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.